版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡介
1、Rat model for the pituitary adenoma induced by estradiol and a study on the relation between NPY and Pituitary adenoma[Background]: In recent years, a great improvement in the study of Neuropeptide Y has been made in the
2、 field of neurophysiology. Neuropeptide Y (NPY), a 36-amino acid member of the pancreatic polypeptide family, was found to be present by Radioimmunoassay (RIA) and immunocytochemistry in the rat's anterior pituitary glan
3、d. It is a peptide originally isolated from porcine brain tissue by Tatemoto K,et al in the early1982 and subsequently shown to be widely distributed in the body of several species, including man, rat, rabbit and so on.
4、These species neuropeptide Y almost have same structural formula just the NPY of porcine has a different amino acid at the 17th position. At present, most scientists regard NPY as neurotransmitter and neuromodulator with
5、 complex effect. In central nervous system, NPY can regulate blood pressure(BP) ,hormone release of hypothalamic-pituitary and have a relation to some disease. In peripheral nervous system, Neuropeptide Y regulates the f
6、unction of cardiovascular system, gastrointestinal tract, respiratory tract,genitourinary system and so on.[Objective]: To find the relation of neuropeptide Y and pituitary adenoma.[Method]: We used 40 Wistar-Furth
7、 female rats in this experiment. They are divided into two groups: Experimental group and Comparison group. The rats of experiment group were injected benzoic acid estradiol in order to induce pituitary adenoma.After 9
8、0 days, rat's plasma prolactin(PRL) was measured by radioimmunoassay(RIA). Neuropeptide Y of rat's pituitary gland and plasma are measured in the same way also used immunohisotchemistry to determine NPY in p
9、ituitary tissue. [Result]: We found the following results: 1-The weight of experiment group rat's pituitary gland is 50-60mg (90days).The experiment group has a significantly heavier pituitary weight than compari
10、son group(p<0.01).Serum PRL level of experimental group is 198.23 ± 93.07 ng/ml (90days).Also,statistical significance showed a higher value than those of comparison group(p<0.001). Histological changes showed that chrom
11、ophobic cells are mainly seen and the number of acidophil cells drop relatively. Malignant cells are not found. Based on the induction theory of Clifton: Rat's pituitary weights over 30mg and level of PRL in the serum is
12、 higher than normal. We think our experiment of inducing rat pituitary adenoma is successful. 2- The level of Neuropeptide Y in blood plasma significantly lower than those of comparison group (p<0.01). And the level
13、of Neuropeptide Y in pituitary gland is significantly lower than those of comparison group (p<0.001). 3- There was a significant positive relation for the level of Neuropeptide Y between pituitary adenoma tissue and s
14、erum. So we can evaluate the level of neuropeptide Y in pituitary gland by the level of neuropeptide Y in serum plasma. [Conclusion]: Estradiol can induce pituitary adenoma of Wistar-Furth rat andserum PRL level
15、was higher than that of comparison group. Neuropeptide Y can be detected lower in pituitary adenoma and plasma in the experiment group. And because it is reported that neuropeptide Y had an effect on the regulati
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 眾賞文庫僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 垂體腺瘤患者血漿神經(jīng)肽y與垂體激素水平相關(guān)性的研究.pdf
- 神經(jīng)肽Y及其受體在垂體腺瘤中的表達(dá)及意義.pdf
- 神經(jīng)肽Y的表達(dá)與垂體腺瘤增殖性、侵襲性及各激素分泌類型關(guān)系的研究.pdf
- 垂體腺瘤
- 垂體腺瘤的顯微外科治療技術(shù)探討(附535例垂體腺瘤臨床分析).pdf
- 雌激素誘發(fā)大鼠垂體腺瘤模型的實(shí)驗(yàn)研究.pdf
- 垂體腺瘤顯微經(jīng)蝶手術(shù)與垂體功能保護(hù)技術(shù)探討.pdf
- 垂體腺瘤 ppt課件
- 垂體腺瘤臨床路徑
- 侵襲性垂體腺瘤綜合治療及Ki-67抗原表達(dá)與垂體腺瘤侵襲性的關(guān)系.pdf
- Galectin-3、Ki-67在垂體腺瘤中的表達(dá)及與垂體腺瘤侵襲性的關(guān)系.pdf
- 垂體性高血壓伴垂體微腺瘤的mri診斷價(jià)值探討
- 垂體腺瘤的外科治療.pdf
- Leptin、PTTG、NCAM、Ki67在垂體腺瘤中的表達(dá)及與垂體腺瘤侵襲性的關(guān)系.pdf
- 垂體瘤轉(zhuǎn)化基因(PTTG)在雌激素誘導(dǎo)的大鼠垂體腺瘤中的表達(dá).pdf
- 垂體腺瘤質(zhì)地與垂體腺瘤類型、MRI信號(hào)、血供及卒中相關(guān)分析.pdf
- 垂體腺瘤的診斷與外科治療.pdf
- 神經(jīng)內(nèi)鏡下經(jīng)鼻蝶垂體腺瘤手術(shù)探討.pdf
- 垂體腺瘤的護(hù)理查房
- 垂體FSH腺瘤及其與無激素腺瘤的臨床對(duì)照研究.pdf
評(píng)論
0/150
提交評(píng)論